GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioDynamics PLC (OTCPK:OXBOF) » Definitions » Sloan Ratio %

Oxford BioDynamics (Oxford BioDynamics) Sloan Ratio % : -12.27% (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Oxford BioDynamics Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Oxford BioDynamics's Sloan Ratio for the quarter that ended in Sep. 2023 was -12.27%.

As of Sep. 2023, Oxford BioDynamics has a Sloan Ratio of -12.27%, indicating there is a warning stage of accrual build up.


Oxford BioDynamics Sloan Ratio % Historical Data

The historical data trend for Oxford BioDynamics's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioDynamics Sloan Ratio % Chart

Oxford BioDynamics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.92 -37.02 -23.35 -24.54 -11.86

Oxford BioDynamics Semi-Annual Data
Sep13 Sep14 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.48 -14.28 -25.28 9.00 -12.27

Competitive Comparison of Oxford BioDynamics's Sloan Ratio %

For the Biotechnology subindustry, Oxford BioDynamics's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford BioDynamics's Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioDynamics's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Oxford BioDynamics's Sloan Ratio % falls into.



Oxford BioDynamics Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Oxford BioDynamics's Sloan Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Sloan Ratio=(Net Income (A: Sep. 2023 )-Cash Flow from Operations (A: Sep. 2023 )
-Cash Flow from Investing (A: Sep. 2023 ))/Total Assets (A: Sep. 2023 )
=(-13.399--10.265
--0.767)/19.959
=-11.86%

Oxford BioDynamics's Sloan Ratio for the quarter that ended in Sep. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Sep. 2023 )
=(-13.292--10.139
--0.704)/19.959
=-12.27%

For company reported semi-annually, GuruFocus uses latest two semi-annual data as the TTM data. Oxford BioDynamics's Net Income for the trailing twelve months (TTM) ended in Sep. 2023 was -5.392 (Mar. 2023 ) + -7.9 (Sep. 2023 ) = $-13.29 Mil.
Oxford BioDynamics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2023 was -6.337 (Mar. 2023 ) + -3.802 (Sep. 2023 ) = $-10.14 Mil.
Oxford BioDynamics's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2023 was -3.184 (Mar. 2023 ) + 2.48 (Sep. 2023 ) = $-0.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oxford BioDynamics  (OTCPK:OXBOF) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Sep. 2023, Oxford BioDynamics has a Sloan Ratio of -12.27%, indicating there is a warning stage of accrual build up.


Oxford BioDynamics Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Oxford BioDynamics's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford BioDynamics (Oxford BioDynamics) Business Description

Traded in Other Exchanges
Address
Oxford Business Park South, 3140 Rowan Place, John Smith Drive, Oxford, GBR, OX4 2WB
Oxford BioDynamics PLC is a biotechnology company. The company focuses on the discovery and development of biomarkers for use within the pharmaceutical and biotechnology industry. It provides a technology platform Episwitch which aims to accelerate the drug discovery and development process and improve the success rate of therapeutic product development. Geographically, the majority of revenue is from The United Kingdom.

Oxford BioDynamics (Oxford BioDynamics) Headlines

From GuruFocus